mercaptoundecanoic acid | 88240-66-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: mercaptoundecanoic acid
• 英文别名: MUA；2-mercapto-undecanoic acid；2-Mercapto-undecansaeure；2-Mercapto-undecylsaeure；2-Sulfanylundecanoic acid
• CAS: 88240-66-8
• 化学式: C₁₁H₂₂O₂S
• 分子量: 218.36
• InChiKey: DYAOREPNYXXCOA-UHFFFAOYSA-N

物化性质

• 熔点：
  49-50 °C
• 沸点：
  165-166 °C(Press: 18 Torr)
• 密度：
  0.996±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  38.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  mercaptoundecanoic acid 、 N-(3-pyridylmethylidene)-2-(N,N-dimethylamino)ethylamine 以 甲苯 为溶剂， 反应 2.0h， 以giving 3-(2-dimethylaminoethyl)-5-(n-nonyl)-2-(3-pyridyl)thiazolidin-4-one (3.1 g, 90% yield)的产率得到3-(2-dimethyl-aminoethyl)-5-(n-nonyl)-2-(pyridin-3-yl)thiazolidin-4-one
  参考文献：
  名称：

  Thiazolidin-4-one derivatives and acid addition salts thereof useful for

  摘要：

  以下是由下列一般式（I）表示的噻唑烷-4-酮衍生物及其酸加成盐：##STR1## 其中，R.sup.1和R.sup.2相同或不同，分别表示（i）由一般式--A--R.sup.4表示的残基，其中，A表示单键，C.sub.1-C.sub.8烷基，C.sub.2-C.sub.8烯基或C.sub.2-C.sub.8炔基，而R.sup.4表示氢，C.sub.1-C.sub.12烷基，C.sub.2-C.sub.8烯基，C.sub.3-C.sub.8环烷基或C.sub.1-C.sub.6卤代烷基；或（ii）由下列一般式表示的残基：##STR2## 其中，B表示单键或C.sub.1-C.sub.6烷基，R.sup.5表示氢，C.sub.1-C.sub.6烷基，C.sub.2-C.sub.8烯基，C.sub.3-C.sub.8环烷基，取代硅烷基或取代或未取代芳基，n和n'分别表示2到4的整数，m表示1到3的整数，而m'表示0到2的整数；R.sup.3表示氢，C.sub.1-C.sub.2烷基，烯丙基，2-丙炔基或由下列一般式表示的残基--F--R.sup.9，其中，F表示C.sub.2-C.sub.6烷基，而R.sup.9表示含氮杂环芳基残基或由下列一般式表示的氨基：##STR3## （其中，R.sup.10表示氢，C.sub.2-C.sub.4烷基或C.sub.1-C.sub.4酰基，而R.sup.11表示氢或C.sub.1-C.sub.4烷基，或R.sup.10与R.sup.11组合表示可选地含有其他杂原子的5-至7-成员环氨基。）这些化合物具有选择性的PAF-拮抗活性，非常有用作为预防和治疗PAF引起的疾病，例如各种炎症，过敏性疾病，循环系统疾病和胃肠疾病的药物。

  公开号：

  US05106860A1
• 作为产物：
  描述：

  methyl 2-acetylthioundecanoate 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 以98%的产率得到mercaptoundecanoic acid
  参考文献：
  名称：

  Certain pyridyl-thiazolidin-4-one having anti-ulcer activity

  摘要：

  一种由以下式表示的2-吡啶基噻唑啉-4-酮衍生物：其中R.sub.1和R.sub.2分别为氢原子、C.sub.1-C.sub.20烷基、C.sub.2-C.sub.20烯基、C.sub.2-C.sub.20炔基、芳基、C.sub.3-C.sub.8环烷基或可能具有取代基的芳基烷基，R.sub.3为氢原子、C.sub.1-C.sub.20烷基、C.sub.2-C.sub.20烯基、C.sub.2-C.sub.20炔基、C.sub.3-C.sub.8环烷基或可能具有取代基的芳基烷基，P为吡啶基或其可能具有取代基的N-取代吡啶盐基，所述取代基选自卤原子、氰基、羟基、氨基、低烷基、低烷氧基、低烷基氨基、卤代低烷基、酰基、酰氧基、硫代酰基、酰胺基、羧基、低烷氧羰基、氨基甲酰基、低烷基取代的氨基甲酰基、杂环基和低环烷基，n表示0、1或2的整数，或其药学上可接受的盐，以及作为有效成分的抗溃疡药物，包含上述2-吡啶基噻唑啉-4-酮衍生物或其药学上可接受的盐。

  公开号：

  US05021435A1

文献信息

• ALKALI-DEVELOPABLE PHOTOSENSITIVE RESIN COMPOSITION AND BETA-DIKETONE COMPOUND
  申请人：Yamada Takashi

  公开号：US20100129753A1

  公开（公告）日：2010-05-27

  An alkali developable photosensitive resin composition contains (J) a photopolymerizable unsaturated compound having a structure resulting from the addition reaction of (B) a compound having a β-diketone moiety or a compound having a β-ketoester group to the (meth)acryloyl group of (A) a compound having at least two (meth)acryloyl groups and a hydroxyl group and subsequent esterification of the hydroxyl group of the resulting addition product with (C) a polybasic acid anhydride. The compound having a β-diketone moiety is preferably a novel β-diketone compound represented by general formula (I): wherein R 1 is a C1-C20 alkyl group; R 2 represents R 11 , OR 11 , COR 11 , SR 11 , CONR 12 R 13 , or CN; R 11 , R 12 , and R 13 are each hydrogen, a C1-C20 alkyl group, etc.; a is 0 to 3; and b is 0 to 4.

  一种可由碱显影的光敏树脂组合物，含有（J）一种光聚合不饱和化合物，该化合物的结构是由（B）含β-二酮基团或含β-酮酯基团的化合物与（A）含至少两个(甲基)丙烯酰基团和一个羟基的化合物中的(甲基)丙烯酰基团发生加成反应，并随后将所得加成产物的羟基与（C）多元酸酐进行酯化反应得到的。含β-二酮基团的化合物最好是表示为通用公式（I）的一种新型β-二酮化合物：其中R1是C1-C20烷基团；R2代表R11、OR11、COR11、SR11、CONR12R13或CN；R11、R12和R13分别是氢、C1-C20烷基团等；a是0到3；b是0到4。
• [EN] HYBRID NANOPARTICLES CONTAINING DENDRONS, METHODS OF PRODUCING SUCH HYBRID NANOPARTICLES, AND USES THEREOF<br/>[FR] NANOPARTICULES HYBRIDES CONTENANT DES DENDRONS, PROCÉDÉS DE PRODUCTION DE CES NANOPARTICULES HYBRIDES, ET LEURS UTILISATIONS
  申请人：RHODIA OPERATIONS

  公开号：WO2016201310A1

  公开（公告）日：2016-12-15

  The present disclosure relates to a hybrid nanoparticle comprising a metallic core and at least one lipophilic dendron attached to the surface of the metallic core, and methods of producing such hybrid nanoparticles. The present disclosure also relates to films containing the hybrid nanoparticles described herein.

  本公开涉及一种混合纳米颗粒，包括金属核和至少一个附着在金属核表面的亲脂性树状分子，以及制备这种混合纳米颗粒的方法。本公开还涉及包含所述混合纳米颗粒的薄膜。
• Thiazolidin-4-one derivatives useful for treating diseases caused by
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：US04992455A1

  公开（公告）日：1991-02-12

  Thiazolidin-4-one derivative represented by the folowing general formula (I) and acid addition salts thereof ##STR1## wherein; R.sup.1 and R.sup.2 are the same or different and denote each (i) a residue represented by the general formula --A--R.sup.4 wherein, A denotes a single bond, C.sub.1 -C.sub.8 alkylene, C.sub.2 -C.sub.8 alkenylene, or C.sub.2 -C.sub.8 alkynylene and R.sup.4 denotes hydrogen, C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.8 alkenyl, C.sub.3 -C.sub.8 cycloalkyl, or C.sub.1 -C.sub.6 haloalkyl, or (ii) a residue represented by the general formula (CH.sub.2).sub.n O}.sub.m (CH.sub.2).sub.n' O}B--R.sup.5 wherein, B denotes a single bond or C.sub.1 -C.sub.6 alkylene, R.sup.5 denotes hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.8 alkenyl, C.sub.3 -C.sub.8 cycloalkyl, substituted silyl, or substituted or unsubstituted aryl, n and n' denote each an integer of 2 to 4, m denotes an integer of 1 to 3, and m' denotes an integer of 0 to 2; and R.sup.3 denotes hydrogen, C.sub.1 -C.sub.2 alkyl, allyl, 2-propynyl, or a residue represented by (a) the general formula --CH.sub.2).sub.l R.sup.6 wherein, R.sup.6 denotes halogen, an aryl group substituted or unsubstituted by one or more hydroxy or C.sub.1 -C.sub.4 alkoxy groups, or a residue represented by the general formula --D--R.sup.7 (D denotes oxygen or sulfur and R.sup.7 denotes hydrogen, C.sub.1 -C.sub.4 alkyl, or C.sub.1 -C.sub.4 alkanol) and l denotes an integer of 2 to 4, (b) the general formula --CH.sub.2).sub.k CO--E--R.sup.8 wherein, E denotes oxygen, sulfur, imino, or C.sub.1 -C.sub.4 alkylimino, R.sup.8 denotes hydrogen or C.sub.1 -C.sub.4 alkyl, or --(E--R.sup.8) denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms, and k denotes an integer of 1 to 3, or (c) the general formula --F--R.sup.9 wherein, F denotes C.sub.2 -C.sub.6 alkylene and R.sup.9 denotes a nitrogen-containing heterocyclic aromatic residue or an amino group represented by the general formula ##STR2## (R.sup.10 denotes hydrogen, C.sub.1 -C.sub.4 alkyl, or C.sub.1 -C.sub.4 alkyl or R.sup.10 in combination with R.sup.11 denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms), with the proviso that, when R.sup.1 is hydrogen and R.sup.2 is methyl, R.sup.3 denotes hydrogen, C.sub.1 -C.sub.2 alkyl, 2-propynyl, or a residue represented by (a) the general formula --CH.sub.2).sub.l R.sup.6 wherein, R.sup.6 denotes halogen, an aryl group substituted or unsubstituted by one or more hydroxy or C.sub.1 -C.sub.4 alkoxy groups, or a residue represented by the general formula --D--R.sup.7 (D denotes oxygen or sulfur and R.sup.7 denotes hydrogen, C.sub.1 -C.sub.4 alkyl, or C.sub.1 -C.sub.4 alkanoyl) and l denotes an integer of 2 to 4, (b) the general formula --CH.sub.2).sub.k CO--E--R.sup.8 wherein, E denotes oxygen, sulfur, imino, or C.sub.1 -C.sub.4 alkylimino, R.sup.8 denotes hydrogen or C.sub.1 -C.sub.4 alkyl, or --(E--R.sup.8) denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms, and k denotes an integer of 1 to 3, or (c) the general formula --F--R.sup.9 wherein, F denotes C.sub.2 -C.sub.6 alkylene and R.sup.9 denotes a nitrogen-containing heterocyclic aromatic residue or an amino group represented by the general formula ##STR3## (R.sup.10 denotes hydrogen, C.sub.2 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkanoyl and R.sup.11 denotes hydrogen or C.sub.1 -C.sub.4 alkyl or R.sup.10 in combination with R.sup.11 denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms. Having selective PAF-antagonistic activities, these compounds are very useful as preventive and curative agents for PAF-induced diseases, for example, various kinds of inflammation, allergic diseases, circulatory diseases, and gastro-intestinal diseases.

  硫唑啉-4-酮衍生物由以下一般式（I）和其酸盐表示： 其中；R.sup.1和R.sup.2相同或不同，各自表示（i）由一般式--A--R.sup.4表示的残基，其中，A表示单键，C.sub.1 -C.sub.8烷基，C.sub.2 -C.sub.8烯基，或C.sub.2 -C.sub.8炔基，R.sup.4表示氢，C.sub.1 -C.sub.12烷基，C.sub.2 -C.sub.8烯基，C.sub.3 -C.sub.8环烷基，或C.sub.1 -C.sub.6卤代烷基，或（ii）由一般式(CH.sub.2).sub.n O}.sub.m (CH.sub.2).sub.n' O}B--R.sup.5表示的残基，其中，B表示单键或C.sub.1 -C.sub.6烷基，R.sup.5表示氢，C.sub.1 -C.sub.6烷基，C.sub.2 -C.sub.8烯基，C.sub.3 -C.sub.8环烷基，取代硅基，或取代或未取代芳基，n和n'各自表示2至4的整数，m表示1至3的整数，m'表示0至2的整数；R.sup.3表示氢，C.sub.1 -C.sub.2烷基，烯丙基，2-丙炔基，或由（a）一般式--CH.sub.2).sub.l R.sup.6表示的残基，其中，R.sup.6表示卤素，一个或多个羟基或C.sub.1 -C.sub.4烷氧基取代或未取代的芳基，或由一般式--D--R.sup.7（D表示氧或硫，R.sup.7表示氢，C.sub.1 -C.sub.4烷基，或C.sub.1 -C.sub.4烷醇基）表示的残基，l表示2至4的整数，（b）一般式--CH.sub.2).sub.k CO--E--R.sup.8表示的残基，其中，E表示氧，硫，亚胺，或C.sub.1 -C.sub.4烷基亚胺，R.sup.8表示氢或C.sub.1 -C.sub.4烷基，或--(E--R.sup.8)表示一个含其他杂原子的5-到7-成员环氨基基团，k表示1至3的整数，或（c）一般式--F--R.sup.9表示的残基，其中，F表示C.sub.2 -C.sub.6烷基，R.sup.9表示含氮的杂环芳基残基或由一般式表示的氨基基团##STR2##（R.sup.10表示氢，C.sub.1 -C.sub.4烷基，或C.sub.1 -C.sub.4烷基或R.sup.10与R.sup.11的组合表示含其他杂原子的5-到7-成员环氨基基团），但是，当R.sup.1为氢且R.sup.2为甲基时，R.sup.3表示氢，C.sub.1 -C.sub.2烷基，2-丙炔基，或由（a）一般式--CH.sub.2).sub.l R.sup.6表示的残基，其中，R.sup.6表示卤素，一个或多个羟基或C.sub.1 -C.sub.4烷氧基取代或未取代的芳基，或由一般式--D--R.sup.7（D表示氧或硫，R.sup.7表示氢，C.sub.1 -C.sub.4烷基，或C.sub.1 -C.sub.4醯基）表示的残基，l表示2至4的整数，（b）一般式--CH.sub.2).sub.k CO--E--R.sup.8表示的残基，其中，E表示氧，硫，亚胺，或C.sub.1 -C.sub.4烷基亚胺，R.sup.8表示氢或C.sub.1 -C.sub.4烷基，或--(E--R.sup.8)表示一个含其他杂原子的5-到7-成员环氨基基团，k表示1至3的整数，或（c）一般式--F--R.sup.9表示的残基，其中，F表示C.sub.2 -C.sub.6烷基，R.sup.9表示含氮的杂环芳基残基或由一般式表示的氨基基团##STR3##（R.sup.10表示氢，C.sub.2 -C.sub.4烷基或C.sub.1 -C.sub.4醯基，R.sup.11表示氢或C.sub.1 -C.sub.4烷基或R.sup.10与R.sup.11的组合表示含其他杂原子的5-到7-成员环氨基基团。这些化合物具有选择性PAF拮抗活性，对于PAF诱导的疾病，例如各种炎症、过敏性疾病、循环系统疾病和胃肠道疾病的预防和治疗非常有用。
• [EN] ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES<br/>[FR] RIBONUCLEOSIDES D'ACYLE ET DESOXYRIBONUCLEOSIDES D'ACYLE
  申请人：COGNIS IP MAN GMBH

  公开号：WO2005049633A1

  公开（公告）日：2005-06-02

  The present invention is concerned with acyl ribonucleosides and with acyl deoxyribonucleosides. It is furthermore concerned with an enzymatic process for the manufacture of acyl ribonucleosides and of acyl deoxyribonucleosides. It is furthermore concerned with the use of acyl ribonucleosides and of acyl deoxyribonucleosides for cosmetic and for pharmaceutical purposes and with their use as a food supplement for humans or animals. It is furthermore concerned with compositions containing acyl ribonucleosides and acyl deoxyribonucleosides, whereby these compositions are suitable for cosmetic or for pharmaceutical purposes or as food supplement.

  本发明涉及酰基核糖核苷和酰基脱氧核糖核苷。此外，本发明还涉及一种用于制造酰基核糖核苷和酰基脱氧核糖核苷的酶法过程。此外，本发明还涉及酰基核糖核苷和酰基脱氧核糖核苷在化妆品和药品中的用途，以及它们作为人类或动物的食品补充剂的用途。此外，本发明还涉及含有酰基核糖核苷和酰基脱氧核糖核苷的组合物，这些组合物适用于化妆品或药品或作为食品补充剂。
• Synthesis of water soluble nanocrystalline quantum dots and uses thereof
  申请人：Shih Wei-Heng

  公开号：US20060078490A1

  公开（公告）日：2006-04-13

  An economic, direct synthetic method for producing water soluble QDs that are ready for bioconjugation is provided. The method can produce aqueous QDs with emission wavelengths varying from 400 nm to 700 nm. Highly luminescent metal sulfide (MS) QDs are produced via an aqueous synthesis route. MS QDs are capped with thiol-containing charged molecules in a single step. The resultant MS QDs exhibit the distinctive excitonic photoluminescence desired of QDs and can be fabricated to avoid undesirable broadband emissions at higher wavelengths. This provides a significant improvement over the present complex and expensive commercial processes for the production of QDs. The aqueous QDs are stable in biological fluids over a long period of time. In addition, nontoxic ZnS QDs have been produced with good photoluminescence properties by refluxing the ZnS QD suspensions over a period of time.

  提供了一种经济、直接的合成方法，用于生产水溶性量子点，以便进行生物共轭。该方法可以产生发射波长从400纳米到700纳米不等的水溶性量子点。通过水相合成路线制备了高度发光的金属硫化物（MS）量子点。MS量子点通过单步酰基含硫带电分子封顶。所得到的MS量子点表现出所需的量子点激子光致发光特性，并可制造以避免在更高波长处产生不良宽带发射。这比目前复杂昂贵的商业量子点生产过程有了显著改进。水溶性量子点在生物液体中长时间稳定。此外，通过反流ZnS量子点悬浮液一段时间，已经生产出具有良好光致发光特性的无毒ZnS量子点。